Search trials – HealthDB

Активни:

Намерени 4,781 изпитвания Стр. 13 от 240

Recruiting Phase 2

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

GIST - Gastrointestinal Stromal Tumor GIST GIST Metastatic Cancer Gastro Intestinal Stromal Tumour +1

This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.

Начало: 01.05.2026 Край: 01.10.2028 Възраст: от 18 г.

United States Kumquat Biosciences Inc. NCT07406633

Recruiting

Quadriceps Strengthening ACL Reconstruction

ACL Tear

The purpose of this study is to investigate the effects of quadriceps focused interventions on knee function and biomechanics in adolescent patients with anterior cruciate ligament reconstruction (ACLR)

Начало: 01.05.2026 Край: 01.11.2027 Възраст: 13–17 г.

United States Stanford University NCT07015541

Recruiting

Poly-L-Lactic Acid for Vulvovaginal Tissue Regeneration

Pelvic Organ Prolapse (POP) Cystocele Pelvic Floor Disorder

Pelvic organ prolapse (POP) is a condition characterized by descent of vaginal walls, uterus and cervix, or the perineum and causes a sensation of vaginal bulge and pelvic pressure. Millions of women in the United States are affected, and the number is expected to rise significantly in the coming decades. Current treatments either involve conservative measures or surgery. Surgery may lead to changes in vaginal topography and scar tissue, both of which impact sexual function. There are no treatment options that restore vaginal tissue strength and preserve, even optimize, sensation and blood flow to the vagina. This project will evaluate the use of poly-L-lactic acid (PLLA), an FDA-approved biostimulant for dermatologic use with an expansive safety profile over the past decade, in the treatment of anterior wall POP and its impact on sexual function. Our study will compare intravaginal injection of PLLA vs. placebo in women with stage 2 cystocele and investigate safety and preliminary efficacy of PLLA. Prior study of regenerative biologics for the vulva and vagina have shown great promise, but use of these has not been explored for POP. This randomized controlled trial has the potential to shift the paradigm of prolapse management from surgical reconstruction to regeneration. This shift will prevent the risks of surgery and has the potential to improve sexual function and quality of life by resolving POP.

Начало: 01.05.2026 Край: 01.06.2028 Възраст: от 21 г.

United States Cassandra Kisby NCT07544667

Recruiting Phase 2

Entrectinib as a Single Agent in Upfront Therapy for Children

High Grade Glioma CNS Tumor

This clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1/2/3 or ROS1 fused, high grade glioma or other central nervous system (CNS) tumors.

Начало: 01.05.2026 Край: 01.11.2032 Възраст: до 3 г.

Brazil, Jordan, United States St. Jude Children's Research Hospital NCT06528691

Recruiting Phase 1

Alzheimer's Disease and Faecal Microbiota Transplantation -a Pilot Study

Alzheimer s Disease Faecal Microbiota Transplantation (FMT)

The goal of this study is to assess the feasibility and safety of faecal microbiota transplantation for Alzheimer's disease.

Начало: 01.05.2026 Край: 01.01.2027 Възраст: от 18 г.

Norway University Hospital of North Norway NCT07332260

Recruiting Phase 2

HB-adMSCs for the Treatment of Crohn's Disease

Crohn Disease (CD)

Methodology: Randomized, double-blind, efficacy and safety study of allogeneic HB-adMSCs vs placebo for the treatment of Crohn's Disease with a 16-week treatment period and a safety and efficacy follow up period for 52 weeks post first treatment. Treatment Duration: 16 weeks General Objectives: To assess the efficacy and safety of multiple intravenous infusions of allogeneic HB-adMSCs by improving signs and symptoms of Crohn's Disease in this subject population. Number of Subjects: 46 (23 in each treatment arm) Indication: Crohn's Disease

Начало: 01.05.2026 Край: 01.12.2027 Възраст: 18–65 г.

United States Hope Biosciences Research Foundation NCT07077746

Recruiting Phase 2

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

Prostate Cancer (Adenocarcinoma) mCRPC (Metastatic Castration-resistant Prostate Cancer)

The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received abiraterone acetate.

Начало: 01.05.2026 Край: 01.03.2030 Възраст: от 18 г.

United States Prostate Cancer Clinical Trials Consortium NCT06844383

Recruiting

Virtual Reality Viewing of Unaltered Streetscape Versus Digitally Manipulated Opposite Streetscape to Assess Psychosocial Response in Participants

Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm Psychiatric Disorder

This clinical trial compares virtual reality viewing of an unaltered streetscape versus a digitally manipulated opposite streetscape to assess the psychosocial response in participants. Visible measures of neighborhood factors might be associated with health outcomes and risk factors of those outcomes. Short-term exposure to virtual reality environments representing very high or very low levels of neighborhood physical disorder - presence or absence of garbage/litter, presence or absence of graffiti, presence or absence of an abandoned building, presence or absence of large dumpsters, poor or very well-kept building conditions, poor or very well-kept yard conditions, poor or very well-kept road verge conditions may be a safe and effective way to assess psychosocial response in participants.

Начало: 01.05.2026 Край: 31.12.2026 Възраст: от 18 г.

United States Ohio State University Comprehensive Cancer Center NCT07216534

Recruiting

Peer-Delivered Behavioral Activation in a CCBHC

Major Depressive Disorder Substance Use Disorders

Low-income individuals have limited access to evidence-based interventions for mental health. Peer recovery specialists, individuals in recovery from mental health and/or substance use problems, have the potential to increase access to evidence-based interventions for individuals from low-resource communities, particularly when trained and supervised in models that are acceptable and feasible in these communities. This study will examine the effectiveness and implementation potential of a peer-delivered evidence-based intervention (Behavioral Activation) among individuals receiving services from a community-based treatment setting providing integrated physical and behavioral healthcare.

Начало: 01.05.2026 Край: 15.01.2029 Възраст: от 18 г.

United States Wayne State University NCT07219394

Recruiting

The Analgesic Efficacy of M-TAPA for Laparoscopic Abdominal Surgery in Children

Post Operative Pain

This investigation aims to assess the efficacy of M-TAPA in children undergoing laparoscopic abdominal surgery. Sixty pediatric patients undergoing laparoscopic abdominal surgery under general anesthesia will be enrolled in this single-center study. Preoperatively, participants will be randomly assigned to receive either port-site local anesthetic infiltration or M-TAPA.

Начало: 01.05.2026 Край: 01.04.2027 Възраст: 1–7 г.

Egypt Kasr El Aini Hospital NCT07540689

Recruiting Phase 2

Study of SA+X in the Treatment of Newly Diagnosed AML

Acute Myeloid Leukemia

This is a phase II, open-label, multi-center study evaluating the efficacy and safety of sonrotoclax (SA) in combination with azacitidine (AZA) plus individualized targeted or chemotherapeutic agents in adult participants with newly diagnosed acute myeloid leukemia (AML). Eligible participants will be stratified into different treatment arms based on genetic background (FLT3/IDH1 mutation status) and fitness for intensive chemotherapy. All participants will receive sonrotoclax with dose escalation from 20 mg/day to 320 mg/day, followed by maintenance dosing, which may be temporarily held by the investigator from Day 14 to Day 28 of each 28-day cycle based on the participant's condition, combined with azacitidine 75 mg/m²/day intravenously on Days 1-7. For participants fit for intensive chemotherapy, additional anthracycline (daunorubicin 60 mg/m²/day or idarubicin 10 mg/m²/day on Days 1-3) will be administered. For participants with FLT3 mutations, gilteritinib 80 mg once daily on Days 1-14 will be added; for those with IDH1 mutations, ivosidenib 500 mg once daily on Days 1-28 will be added.

Начало: 01.05.2026 Край: 21.12.2028 Възраст: от 18 г.

China Ruijin Hospital NCT07548710

Recruiting Phase 2

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

FGFR2 Gene Fusion/Rearrangement Other Solid Tumors, Adult

The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or rearrangement. Participants will: * Take lirafugratinib regularly as instructed by their study doctor. * Visit the clinic as instructed for checkups and tests. * Keep a diary recording each time a dose of lirafugratinib is taken.

Начало: 01.05.2026 Край: 01.12.2028 Възраст: от 18 г.

France, South Korea, Spain +2 Elevar Therapeutics NCT07359820

Recruiting

Study of a Peptide Cream's Effect on the Facial Skin Barrier Using a Side-by-Side Comparison

Skin Barrier Function Skin Hydration Topical Peptide Effects on Facial Skin Barrier Function

The goal of this clinical trial is to evaluate whether a topical face cream containing the peptide Acetyl Hexapeptide-37 improves skin hydration and strengthens the skin barrier compared to a placebo cream in healthy adult participants. The study uses a split-face design, in which one side of the face is treated with the peptide cream and the other side with a placebo (a cream without the active ingredient). The main questions it aims to answer are: * Does the peptide cream improve skin hydration and reduce transepidermal water loss compared to placebo? * Does the peptide cream affect skin erythema or cause irritation? * How do participants rate the comfort and tolerability of the peptide cream? Researchers will compare the treated and placebo sides of the face to assess differences in skin barrier function and tolerability. Participants will: * Attend a baseline visit for assessment of facial skin parameters, including hydration, transepidermal water loss, and erythema * Apply the peptide cream to one side of the face and the placebo cream to the other side once daily for 4 weeks * Attend weekly follow-up visits for non-invasive skin measurements * Record any skin sensations (e.g., stinging, tightness) or adverse effects throughout the study

Начало: 01.05.2026 Край: 01.01.2027 Възраст: 18–50 г.

Croatia University of Split, School of Medicine NCT07548424

Recruiting

Endoscopic Application of Tranexamic Acid and Sucralfate in Gastrointestinal Tumor Bleeding: A Randomized Controlled Trial

Bleeding After GI Endoscopy

Background Gastrointestinal bleeding is a common disease among the population in Taiwan, with gastrointestinal tumor bleeding accounting for 3-5% of cases. The pathophysiology of gastrointestinal tumor bleeding is unique, involving fragile surface mucosa, abnormal vascular proliferation, and malformation, making endoscopic hemostasis challenging. Conventional endoscopic hemostasis methods such as hemostatic injections, clips, or thermal coagulation have suboptimal success rates below 80%, with recurrence rates exceeding 50%. Recent clinical trials have demonstrated that hemostatic powder spraying effectively enhances hemostasis for gastrointestinal ulcers and reduces recurrence rates. Our previous research repurposed tranexamic acid in a powder form to enhance hemostasis for peptic ulcer and applied sucralfate powder to prevent postpolypectomy wound bleeding. Study aim Our research team combines previous experience by using tranexamic acid and sucralfate drug powders to spray onto bleeding gastrointestinal tumors to achieve hemostatic effects. Additionally, tumor-derived exosomes are associated with tumor angiogenesis and growth, so we hypothesize that gastrointestinal tumor bleeding may be linked to VEGF and miR-21 expression within gastrointestinal tumor exosomes. Study method This study is a clinical randomized controlled trial conducted at National Cheng Kung University Hospital. We will recruit 60 patients with gastrointestinal tumor bleeding undergoing endoscopic hemostasis. Patients in the experimental treatment group will receive additional topical administration of 1.5 g of tranexamic acid and 3 g of sucralfate drug powder. Immediate hemostasis and 30-day bleeding recurrence will be observed. Enrolled patients will also provide blood and tumor specimens for exosome analysis, evaluating the predictive effect of extracted tumor exosomes' VEGF and miR-21 on bleeding risk. This study will explore the association between specific tumor exosome expression levels and bleeding, serving as a basis for bleeding risk assessment and innovative therapies.

Начало: 01.05.2026 Край: 31.12.2027 Възраст: от 18 г.

Taiwan National Cheng-Kung University Hospital NCT07540026

Recruiting

AI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging

Early Gastric Cancer

Early gastric cancer (EGC) is often difficult to detect accurately during endoscopic examination due to subtle morphological features and variability among endoscopists. Artificial intelligence (AI) has shown promise in improving diagnostic performance; however, most existing models lack interpretability and rely on single-modality imaging. This study aims to develop and evaluate an explainable multimodal artificial intelligence model for the diagnosis of early gastric cancer using endoscopic imaging. The model integrates features derived from white-light imaging and image-enhanced endoscopy, along with quantitative image features and clinical data, to improve diagnostic accuracy and provide interpretable decision support. The primary outcome is the diagnostic performance of the AI model for detecting early gastric cancer, evaluated by area under the receiver operating characteristic curve (AUROC), sensitivity, and specificity. The results of this study are expected to provide evidence for the clinical utility of explainable AI in endoscopic diagnosis and support the development of reliable human-AI collaborative diagnostic systems.

Начало: 01.05.2026 Край: 01.02.2027 Възраст: 18–80 г.

China The First Affiliated Hospital of Soochow University NCT07551466

Recruiting

Contrast-Induced Acute Kidney Injury Prevention in Acute Heart Failure

Heart Failure Acute Renal Dysfunction

The K-PROSE study is a randomized clinical investigation evaluating strategies to prevent contrast-induced acute kidney injury (CI-AKI) in patients hospitalized with acute heart failure and moderate renal dysfunction (eGFR 30-75 mL/min/1.73 m²). Patients requiring contrast-enhanced CT imaging are randomized to either standard intravenous saline hydration or a furosemide-based decongestion strategy. Renal function is assessed using serial measurements of creatinine and cystatin C, before and after contrast exposure. By comparing renal outcomes, congestion status, and safety profiles, this study aims to determine whether a decongestion-focused approach provides superior renal protection compared with conventional hydration in high-risk acute heart failure patients.

Начало: 01.05.2026 Край: 30.01.2029 Възраст: от 20 г.

South Korea Seoul National University Bundang Hospital NCT07550790

Recruiting Phase 2

Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension (PAH)

This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of the study is to see how safe and effective REGN13335 is in participants with PAH who are taking other PAH medicines. The study is looking at several other research questions, including: * What side effects may happen from taking REGN13335 * How much REGN13335 is in the blood at different times * Whether the body makes antibodies against REGN13335 (which could make REGN13335 less effective or could lead to side effects)

Начало: 30.04.2026 Край: 27.09.2028 Възраст: от 18 г.

South Korea, United States Regeneron Pharmaceuticals NCT07318597

Recruiting

Evaluation of the Performance and Safety of a Single-dose Hyaluronic Acid (Promovia Hydro Balance) in the Treatment of Non-traumatic Degenerative Meniscus Tears

Meniscus Tears

Evaluation of the performance and safety of a single-dose hyaluronic acid (Promovia hydro balance) in the treatment of non-traumatic degenerative meniscus tears

Начало: 30.04.2026 Край: 30.01.2027 Възраст: 35–75 г.

Italy Innate srl NCT07539194

Recruiting

FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients

Lung Infection Microbial Colonization Food Intolerance Syndromes

Acute respiratory distress syndrome (ARDS) represents a substantial global health burden. In the intensive care unit (ICU), the concurrent administration of antibiotics, opioids, proton pump inhibitors (PPIs), vasoconstrictors, and parenteral nutrition-compounded by the intrinsic severity of critical illness-induces profound gut microbiota dysbiosis. Accumulating preclinical and clinical evidence indicates that such intestinal dysregulation may trigger distal immunomodulatory and microbial shifts in the lung via the gut-lung axis, thereby contributing to pulmonary microecological imbalance and impairing recovery trajectories. Although pulmonary microecology has garnered increasing scientific attention, the causal and temporal relationship between gut dysbiosis and the establishment or exacerbation of pulmonary microbial dysbiosis in ARDS remains inadequately characterized. As a result, it is currently unclear whether gut dysbiosis serves as a primary pathogenic driver, a disease-amplifying factor, or a secondary epiphenomenon in the context of ARDS-associated lung injury. Fecal microbiota transplantation (FMT) is a targeted microbiome-modulating intervention that involves the transfer of functionally diverse, minimally processed microbial communities from comprehensively screened healthy donors to restore ecological stability and functional redundancy in the recipient gut. Robust clinical data demonstrate that FMT effectively decolonizes the gastrointestinal tract of multidrug-resistant organisms (MDROs) and reduces the incidence of secondary infections in immunocompetent, non-critically ill populations. Over the past decade, FMT has demonstrated reproducible efficacy in recurrent Clostridioides difficile infection and emerging promise in select extra-intestinal inflammatory conditions-highlighting its capacity as a mechanism-informed strategy for systemic host-microbe recalibration. Given the established role of the gut as a reservoir for enteric pathogens implicated in sepsis, hospital-acquired bloodstream infections, and ventilator-associated pneumonia (VAP), we propose a prospective, single-center, open-Label, randomized controlled trial (RCT) enrolling mechanically ventilated adults with ARDS. The primary objective is to evaluate whether adjunctive FMT-delivered via nasojejunal tube-decrease 28-day mortality.

Начало: 30.04.2026 Край: 31.12.2026 Възраст: 18–70 г.

China Union Hospital, Tongji Medical College, Huazhong Univer NCT06970262

Recruiting

A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

Parkinson's Disease

This is an observational study in which data are collected and studied from Parkinson's disease patients who have movement symptoms despite taking standard Parkinson's medications. In observational studies, observations are made without any changes to the participant's healthcare or treatment plan. No investigational product will be administered in this study, as participants will be treated with the standard of care that medical experts currently consider most appropriate. Parkinson's disease (PD) is a condition that affects the brain and causes problems with movement and other body functions. The symptoms of Parkinson's disease can worsen over time. People with Parkinson's disease may experience shaking (tremor), slow movements, stiff muscles, trouble walking, and problems with balance. They can also have other symptoms, such as difficulty thinking clearly, changes in mood, or difficulty sleeping. Parkinson's disease mostly affects older adults, but it can happen to younger people too. There is no cure, but treatments can help manage the symptoms and improve quality of life. While doctors and researchers know that Parkinson's disease affects people in different ways and can worsen over time, there are still many things they don't fully understand-especially for people who experience movement symptoms despite taking their usual Parkinson's medicines. Earlier studies did not follow these patients long enough or collect all the important information needed. This study is being done to fill those gaps. The main purpose of this study is to better understand how Parkinson's disease changes over time in patients who experience movement symptoms while taking standard oral Parkinson's medications, what challenges patients and their care partners face, and how their treatments are working in real life. To do this, researchers will collect data on: * Sociodemographics (e.g. age, gender, race/ethnicity, insurance provider). * Medical history and vital signs (e.g. comorbidities, family history of Parkinson's, height, weight, blood pressure). * Medications and treatments (e.g. Parkinson's and non-Parkinson's medications and other treatments, rehabilitation therapy sessions, use of mobility assistance devices). * Movement symptoms (e.g. tremor, slow movement, balance). * Non-movement symptoms (e.g. cognition, mood, sleep, activities of daily living). * Molecular data (e.g. genetics, α-synuclein). * Burden of care (e.g. economic cost). Data will come from questionnaires or rating scales conducted by the doctor with the patient during study visits, diaries and logs completed by the patient, medical records, health insurance claims records, blood samples and skin biopsies, a digital device that records movement/non-movement symptoms, and questionnaires completed by the care partner. Data will be collected from December 2025 to December 2032. Each participant may be followed for up to 5 years.

Начало: 30.04.2026 Край: 01.06.2033 Възраст: 45–75 г.

United States Bayer NCT07330258

1 … 11 12 13 14 15 … 240